Physician profile
Ankur Bindal
NPI 1588820880
$26,685.69
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $5,373 · 2021: $7,079 · 2022: $2,258 · 2023: $424 · 2024: $931 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.53 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17,160.82 | 2019-2023 | Austedo Xr |
| Neuronetics, INC. | $5,805.61 | 2019-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $639.98 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $400.00 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $349.04 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $345.50 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $307.99 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $263.74 | 2020-2022 | |
| Lundbeck LLC | $255.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.93 | 2020-2022 | |
| Abbvie INC. | $175.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $162.79 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $148.55 | 2024 | |
| Janssen Pharmaceuticals, INC | $116.33 | 2019-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $88.74 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $64.16 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $57.71 | 2019 | |
| Allergan, INC. | $36.70 | 2020 | |
| Avanir Pharmaceuticals, INC. | $33.35 | 2019-2021 | |
| Eisai INC. | $28.21 | 2020-2021 | |
| Bausch Health US, LLC | $23.33 | 2022 | |
| Livanova USA, INC. | $18.35 | 2021 | |
| Almatica Pharma LLC | $16.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Bindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.